HomeAI · summaries
Storia in 14 fonti
Dow Jones Top Company Headlines at 9 AM ET: GSK to Buy Nuvalent for $10.6 Billion in Oncology Push | J.M. ...
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
cnbc.com
GSK in talks to acquire Nuvalent for more than $9 billion in biggest deal in over a decade: FT
The deal comes at a time of biotech dealmaking frenzy, driven by looming patent cliffs, newly buoyant public markets and drugmakers' race to bolster pipelines.
- ·
thehindubusinessline.com
GSK in talks to buy cancer biotech Nuvalent for more than $9 billion
GSK is in negotiations to acquire cancer biotech Nuvalent for over $9 billion amid a surge in biotech mergers.
- ·
cityam.com
GSK snaps up US cancer treatment firm Nuvalent in $10.6bn deal
GSK has bought a Boston-based biopharmaceutical firm that specialises in lung cancer treatment in a $10.6bn deal.
- ·
endpoints.news
GSK to acquire Nuvalent and its two cancer drugs under FDA review for $10.6B
GSK to acquire Nuvalent for $10.6B, gaining two lung cancer drugs — zidesamtinib and neladalkib — both under FDA review in 2026.
- ·
statnews.com
GSK to buy Nuvalent, maker of targeted cancer drugs, for $10.6B
GSK is buying Nuvalent, the maker of targeted cancer drugs, for $10.6 billion, a sizable addition to the latest run of biopharma acquisitions.
- ·
independent.co.uk
GSK to buy US lung cancer drug specialist Nuvalent for £8bn
The acquisition is thought to be GSK’s biggest deal in more than a decade.
- ·
morningstar.com
Dow Jones Top Company Headlines at 3 AM ET: GSK to Buy Nuvalent for $10.6 Billion in Oncology Push | University ...
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
- ·
hindustantimes.com
UK pharma giant GSK to buy US-based cancer drugmaker Nuvalent for $10.6 billion
GSK Plc is set to acquire Nuvalent for $10.6 billion, paying $124 per share. The move aims to boost GSK's oncology treatments. | Business News
- ·
Dow Jones Top Company Headlines at 5 AM ET: GSK to Buy Nuvalent for $10.6 Billion in Oncology Push | University ...
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
- ·
barrons.com
Nuvalent Stock Jumps 39% on Surprise GSK Cancer-Drug Deal
Nuvalent stock soars after GSK says it has agreed to buy the cancer-drug developer for $10.6 billion.
- ·
benzinga.com
GSK Makes Its Biggest Bet In More Than A Decade, Paying $10.6 Billion For Cancer Drug Developer Nuvalent
GSK will acquire Nuvalent for $10.6 billion to expand its lung cancer pipeline as Nuvalent shares surge nearly 39%.
- ·
Dow Jones Top Company Headlines at 7 AM ET: GSK to Buy Nuvalent for $10.6 Billion in Oncology Push | University ...
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
- ·
newsbytesapp.com
GSK buys US biopharma company Nuvalent for $10.6B
Britain's GSK has announced its $10.6 billion acquisition of US-based cancer-focused biopharma firm Nuvalent, paying a 40% premium at $124 per share in cash.
- ·
malaymail.com
GSK offers 40pc premium in US$10.6b bid for cancer drug developer Nuvalent
Deal values cancer drug developer Nuvalent at US$124 (RM503) per shareThat is a 40 per cent premium to the US-listed firm’s close yesterdayGSK CEO Miels says deals expands lung...
- ·
Dow Jones Top Company Headlines at 9 AM ET: GSK to Buy Nuvalent for $10.6 Billion in Oncology Push | J.M. ...
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
- ·
Pharmalittle: We're reading about a $10.6 billion GSK deal, an AstraZeneca obesity pill, and more
GSK agreed to buy Nuvalent, a cancer drug developer, in a deal worth $10.6 billion, as the company continues its expansion in oncology
- ·
Gilead and Merck's latest trial success and flop
AstraZeneca's GLP-1 pill, GSK's $10.6B cancer startup acquisition, and more biotech news from The Readout
- ·
Dow Jones Top Company Headlines at 11 AM ET: GSK to Buy Nuvalent for $10.6 Billion in Oncology Push | J.M. ...
GSK to Buy Nuvalent for $10.6 Billion in Oncology Push
- ·
ilsole24ore.com
Gsk acquisisce Nuvalent per 10,6 miliardi nel top deal degli ultimi dieci anni
L’accordo attribuisce a Nuvalent una valutazione di circa 124 dollari per azione, con un premio del 40% rispetto all’ultimo prezzo di chiusura
- ·
expansion.com
GSK compra Nuvalent por 9.200 millones para crecer en oncolog�a
Se trata de la mayor adquisici�n de GSK en m�s de una d�cada y es la primera gran transacci�n del nuevo CEO, Luke Miels, que asumi� las riendas del laboratorio brit�nico el...